Alena Kreychman
Baystate Medical Center, USA
Title: Xofigo, radioactive ra 223 treatment of castrate resistant prostate bony metastasis
Biography
Biography: Alena Kreychman
Abstract
Xofigo is an alpha-particle emitting radio isotope radium-223 dichloride. The drug mimics calcium and forms complexes with the bone mineral at sites of bone metastatses. It then emits alpha particles, causing the destruction of DNA in nearby cells, resulting in cancer cell death in the bone. Xofigo is the only therapeutic radiopharmaceutical in treatment of bony metastasis. When it comes to unsealed sources of radiation, this is the first one that has shown significant survival benefits. That is a historical event in the radiotherapies. There are also secondary benefits, including delaying time to first skeletal-related event. It is also the first alpha emitter that has been FDA approved. The critical feature of an alpha emitter is that it is a much more powerful particle, which travels a shorter distance while hitting the cancer cells harder and avoding the healthy cells, so the complication rates are decreased. Because of those reasons, Xofigo is really making a huge impact in the history of oncologic interventions.